Malignant fibrous histiocytoma is extremely rare primary malignant tumor of the heart. It is usually diagnosed when it is locally aggressive or has already metastasized. The prognosis is poor with the average survival time of one year. We report a case of recurrent left atrial malignant fibrous histiocytoma initially misdiagnosed as myxoma. The patient underwent repeated surgical resections followed by chemotherapy. Despite adjuvant chemotherapy, 18 months after initial diagnosis definitive tumor relapse in left atrium was diagnosed. This is the 48 th case of primary cardiac fibrous malignant histiocytoma reported in literature.
Introduction
Primary cardiac tumors are rare, with an autopsy incidence ranging from 0.001% to 0.03% (1) . About three-quarters of these tumors are benign and nearly half of them are myxomas.
Malignant fibrous histiocytoma (MFH) is the most common soft tissue sarcoma in adults, but is extremely rare as a primary tumor of the heart (2). MFH is a malignant tumor of fibriblasts and pleomorphic histiocytoid cells with large number of bizarre, multi-nucleated giant cells.
Their stroma might be sometimes myxoid and moreover they might be occasionally misdiagnosed as a myxoma (3) . Cardiac tumors present with one or more symptoms of the classic triad: intracardiac obstruction, systemic embolisation and systemic symptoms like fever, arthralgia, weight loss and fatigue. The prognosis of patients having even nonmetastatic primary cardiac sarcomas is relatively poor with very few patients surviving for more than one year after diagnosis (4). Reasons for this dismal outcome are the diagnosis of this type of tumors in advanced stage of disease, impossibility to perform adequate radical tumor excision and the cardiotoxic side effects of radiotherapy and of some cytotoxic drugs (5) . Early cardiac transplantation, if possible, might be a promising therapy for patients with nonmetastatic malignant cardiac sarcomas (6) . We present the female patient with the malignant fibrous histiocytoma of the left atrium.
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Case report
A 58 year-old white woman was admitted to our hospital in September 2003 with history of congestive heart failure and bilateral pleural effusion three months ago. She underwent total thyreoidectomy with paraglandular resection and subsequent radioactive iodide administration in 2000 because of papillar carcinoma of a thyroid gland. On admission she was eupnoic in rest and afebrile, blood pressure was 140/90 mmHg, heart rate was regular, 96 beats/min. Electrocardiogram revealed sinus rhythm with occasional extrasystolas.
Pulmonary, cardiac and abdominal examination was unremarkable. There were no palpable lymph nodes. Transthoracic (TTE) and transesophageal echocardiography (TEE) revealed large, partially mobile tumorous mass 4x2 cm in the left atrium, which was partially obstructing blood flow through the mitral valve. According to its localization and appearance on echocardiography the tumor was suggestive for myxoma. No other tumor was found in the chest and abdomen. Open heart surgery under cardiopulmonary bypass was done and tumor was successfully resected; histopathology diagnosis was myxoma. Control TTE in Chemotherapy has also its limitations such as a relatively low response rates. Moreover, doxorubicin which is effective chemotherapeutic drug and therefore commonly used for the 8 soft tissue sarcomas is cardiotoxic what limits its usage and effectiveness in patients having cardiac sarcomas (9) . For patients with unresectable or partially resectable heart sarcomas radiation and chemotherapy may be used, but without great expectation of long term tumor control. Limited evidence shows that selected patients with nonmetastasing MFH can benefit from orthotopic cardiac transplantation (6) cardiotoxicity. In the case of soft tissue sarcoma distant spread is by the hematogenous route and lung metastases are the commonest metastatic site followed by bone and liver.
Metastases in soft tissue are much rarer except in alveolar soft part sarcoma. The presented patient during our follow-up has never developed metastases at the lung, bone or liver.
Moreover, two distant metastases she developed were both in the skeletal muscles what is for the soft tissue sarcomas and probably for the heart sarcomas a rather peculiar metastatic sites. Strict follow-up of patients with MFH is mandatory because it has a high rate of recurrence and metastasing. Development of an optimal therapy for MFH will need improved understanding of the natural history and prognostic factors of this very rare disease.
Adjunctive chemotherapy in conjunction with resection remains the first line therapy. The 9 potential gain of radiotherapy must be weighed against the risk of damage to myocardium and pericardium. The role of cardiac transplantation for primary cardiac MFH should be weighed on a case-by -case basis for patients who present with unresectable tumor and no extracardiac evidence of disease. 
